OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Sidea Semiconductor Equipment
301629
US Stock MarketDetailed Quotes
CATX Perspective Therapeutics
- 2.1300
- -0.0700-3.18%
Close Mar 31 16:00 ET
- 2.1300
- 0.00000.00%
Post 20:01 ET
157.73MMarket Cap-1.73P/E (TTM)
2.2050High2.0100Low979.12KVolume2.1600Open2.2000Pre Close2.09MTurnover1.80%Turnover RatioLossP/E (Static)74.05MShares19.050052wk High0.54P/B116.22MFloat Cap2.010052wk Low--Dividend TTM54.56MShs Float85.0000Historical High--Div YieldTTM8.86%Amplitude0.0300Historical Low2.1330Avg Price1Lot Size
About Perspective Therapeutics Company
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
Company Profile
SymbolCATX
Company NamePerspective Therapeutics
Listing DateApr 19, 2007
Founded1983
CEOMr. Johan M. Spoor
MarketAMEX
Employees140
Fiscal Year Ends12-31
Address2401 Elliott Avenue,Suite 320
CitySeattle
ProvinceWashington
CountryUnited States of America
Zip Code98121
Phone1-206-676-0900
Company Executives
- Name
- Position
- Salary
- Johan M. Spoor
- Director and Chief Executive Officer
- 1.46M
- Dr. Markus Puhlmann, M.D.,PhD
- Chief Medical Officer
- 900.09K
- Juan Graham
- Chief Financial Officer
- --
- Jonathan R. Hunt
- Chief Accounting Officer
- 1.17M
- Lori A. Woods
- Chairman of the Board
- 671.73K
- Heidi Henson, C.P.A.
- Independent Director
- 390.70K
- Robert Froman Willian, III
- Independent Director
- 320.06K
- Dr. Frank Morich, M.D.,PhD
- Independent Director
- 320.06K
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025